{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:10:40Z","timestamp":1789161040947,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["281493"],"award-info":[{"award-number":["281493"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["Institutional funding"],"award-info":[{"award-number":["Institutional funding"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005413","name":"Universit\u00e9 Paris Descartes","doi-asserted-by":"publisher","award":["Institutional funding"],"award-info":[{"award-number":["Institutional funding"]}],"id":[{"id":"10.13039\/501100005413","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Day Solvay"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Endocrinologie et Diab\u00e9tologie P\u00e9diatrique"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00125-018-4638-7","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T09:52:12Z","timestamp":1527587532000},"page":"1811-1816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice"],"prefix":"10.1007","volume":"61","author":[{"given":"Alix","family":"Besan\u00e7on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Vanhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Chatenoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvaine","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"4638_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378:412\u2013419","journal-title":"Lancet"},{"key":"4638_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1074-7613(00)80323-4","volume":"5","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow DJ, Herold KC, Rhee L et al (1996) CD28\/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285\u2013293","journal-title":"Immunity"},{"key":"4638_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","volume":"12","author":"B Salomon","year":"2000","unstructured":"Salomon B, Lenschow DJ, Rhee L et al (2000) B7\/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431\u2013440","journal-title":"Immunity"},{"key":"4638_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 Costimulation: from mechanism to therapy. Immunity 44:973\u2013988","journal-title":"Immunity"},{"key":"4638_CR5","doi-asserted-by":"publisher","first-page":"17ra10","DOI":"10.1126\/scitranslmed.3000116","volume":"2","author":"N Poirier","year":"2010","unstructured":"Poirier N, Azimzadeh AM, Zhang T et al (2010) Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2:17ra10","journal-title":"Sci Transl Med"},{"key":"4638_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ajt.12964","volume":"15","author":"N Poirier","year":"2015","unstructured":"Poirier N, Dilek N, Mary C et al (2015) FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant 15:88\u2013100","journal-title":"Am J Transplant"},{"key":"4638_CR7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4049\/jimmunol.1402563","volume":"194","author":"KG Haanstra","year":"2015","unstructured":"Haanstra KG, Dijkman K, Bashir N et al (2015) Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis. J Immunol 194:1454\u20131466","journal-title":"J Immunol"},{"key":"4638_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/cei.12739","volume":"183","author":"MP Vierboom","year":"2016","unstructured":"Vierboom MP, Breedveld E, Kap YS et al (2016) Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol 183:405\u2013418","journal-title":"Clin Exp Immunol"},{"key":"4638_CR9","doi-asserted-by":"publisher","first-page":"e89381","DOI":"10.1172\/jci.insight.89381","volume":"2","author":"M Zaitsu","year":"2017","unstructured":"Zaitsu M, Issa F, Hester J, Vanhove B, Wood KJ (2017) Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses. JCI Insight 2:e89381","journal-title":"JCI Insight"},{"key":"4638_CR10","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.4049\/jimmunol.171.7.3348","volume":"171","author":"Q Tang","year":"2003","unstructured":"Tang Q, Henriksen KJ, Boden EK et al (2003) Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171:3348\u20133352","journal-title":"J Immunol"},{"key":"4638_CR11","doi-asserted-by":"publisher","first-page":"e0171822","DOI":"10.1371\/journal.pone.0171822","volume":"12","author":"PH Papotto","year":"2017","unstructured":"Papotto PH, Marengo EB, Sardinha LR et al (2017) Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-gamma production. PLoS One 12:e0171822","journal-title":"PLoS One"},{"key":"4638_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/ajt.12574","volume":"14","author":"H Xu","year":"2014","unstructured":"Xu H, Perez SD, Cheeseman J, Mehta AK, Kirk AD (2014) The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant 14:319\u2013332","journal-title":"Am J Transplant"},{"key":"4638_CR13","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1084\/jem.20112607","volume":"209","author":"DK Finlay","year":"2012","unstructured":"Finlay DK, Rosenzweig E, Sinclair LV et al (2012) PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med 209:2441\u20132453","journal-title":"J Exp Med"},{"key":"4638_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.immuni.2011.01.012","volume":"34","author":"AN Macintyre","year":"2011","unstructured":"Macintyre AN, Finlay D, Preston G et al (2011) Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34:224\u2013236","journal-title":"Immunity"},{"key":"4638_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/eji.201746923","volume":"47","author":"L Laurent","year":"2017","unstructured":"Laurent L, Le Fur A, Bloas RL et al (2017) Prevention of lupus nephritis development in NZB\/NZW mice by selective blockade of CD28. Eur J Immunol 47:1368\u20131376","journal-title":"Eur J Immunol"},{"key":"4638_CR16","first-page":"580","volume":"123","author":"R Zhang","year":"2013","unstructured":"Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA (2013) An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 123:580\u2013593","journal-title":"J Clin Invest"},{"key":"4638_CR17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2337\/db09-1324","volume":"59","author":"VP Houde","year":"2010","unstructured":"Houde VP, Br\u00fbl\u00e9 S, Festuccia WT et al (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338\u20131348","journal-title":"Diabetes"},{"key":"4638_CR18","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","volume":"355","author":"DW Lamming","year":"2012","unstructured":"Lamming DW, Ye L, Katajisto P et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 355:1638\u20131643","journal-title":"Science"},{"key":"4638_CR19","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","volume":"197","author":"N Poirier","year":"2016","unstructured":"Poirier N, Blancho G, Hiance M et al (2016) First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28. J Immunol 197:4593\u20134602","journal-title":"J Immunol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4638-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:02:20Z","timestamp":1559080940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4638-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4638"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4638-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BV and CM are current employees of OSE Immunotherapeutics (formerly Effimune SAS). The pegylated anti-CD28 Fab\u2032 antibody fragment (PV1-PEG) is the property of OSE Immunotherapeutics, Nantes, France. AB, FV, TG, LC and SY declare no commercial or financial conflict of interest. The study sponsor was not involved in: the design of the study; the collection, analysis or interpretation of data; writing the report; or the decision to submit the report for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}